SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Drug Development
Realizing Gene Therapy and Cell Regeneration in Heart Disease
After decades of treating the big categories of heart disease – hypertension, for example – the ability to address the genetics of heart disease is within sight.
January 23, 2022
 · 
4 min read
 · 
Gail Dutton
Business
Foresite Labs Hatches Big-Data-Driven Companies Destined to Shake up Healthcare
Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.
January 20, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Early Career Shift Serendipitous for Kinaset CEO Robert Clarke, Asthma Patients
The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.
January 18, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
Aria Deploys AI Differently to Drive New Insights
Aria Pharmaceuticals is using a unique computational approach to drug development that has increased its success rate by 30-fold when compared to traditional approaches.
January 15, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Novel Vaccines with Novel Targets Emerge at Biotech Showcase
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
January 14, 2022
 · 
4 min read
 · 
Gail Dutton
Biotech Beach
Cardiometabolic Syndrome: Overlooked & Poised to Boom as Digital Tech Peaks
Cardiometabolic disease is an overlooked therapeutic space that represents a huge and growing need as the global population ages, according to panelists speaking at Biotech Showcase.
January 13, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Outsmarting Cancer: Next Generation Therapies
Protein degradation, cell therapy, synergistic combinations and changes in personalized cancer therapies will drive the next generation of therapeutics...
January 12, 2022
 · 
4 min read
 · 
Gail Dutton
BioMidwest
For mRNA Vaccines, Protection is Down to the T Follicular Helper Cells
T follicular helper immune cells help antibody-producing cells create increasingly robust antibodies and also enhance the formation of certain types of immune memory.
January 11, 2022
 · 
4 min read
 · 
Gail Dutton
Business
CEO to CEO: Tips for First-time Founders
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders.
January 10, 2022
 · 
6 min read
 · 
Gail Dutton
Drug Development
Precision Gene Therapy on the Cusp
The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date: the risk of unintended consequences.
January 9, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Cartesian Aims to Propel RNA Cell Therapy with Combinations
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies.
January 6, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
New IHU Variant On CDC’s Radar But Currently Not a Concern
What the appearance of yet another variant shows is the “unpredictability of the emergence of SARS-CoV-2 variants,” according to the researchers who discovered IHU.
January 6, 2022
 · 
4 min read
 · 
Gail Dutton
Virtual JPM Week and Satellite Conferences Tout Increased Engagement Opportunities
Overall, the decision to hold the conferences virtually again this year is being met with what appears to be a bit of relief.
January 5, 2022
 · 
5 min read
 · 
Gail Dutton
Beyond the Business Pitch - Plan, Build Relationships and Deliver Succinctly
This year’s virtual J.P. Morgan Week is spurring companies to expand meeting slots throughout the month and conduct more relaxed, productive encounters.
January 4, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
Incoming CEO Andy Kidd Prepares to Take Aptinyx to the Next Level
Right now, Kidd’s focus is on ensuring the company is ready for late-stage development and commercialization activities.
January 3, 2022
 · 
4 min read
 · 
Gail Dutton
Load More